The MRA treatment decreased the mRNA levels of CD3E, CD4 and CD45 compared to the CKD HFD (Figure 4A), while gene expression of the CD68 marker is unaffected (Figure 4A). This evidence concerns the gene PTPRC and chronic kidney disease.